Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Nov. 12, 2024 — Researchers have found that the way DNA is packaged in cells can directly impact how fast DNA itself is copied during cell division. They discovered that DNA packaging sends ...

Presented New CRB-913 Pre-Clinical Data at Obesity Week 2024 - Phase 1 Trial Expected to Commence in Q1 2025 ...

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by ...

Monlunabant was evaluated in a phase 2a trial (ClinicalTrials.gov Identifier: NCT05891834) in patients with obesity and metabolic syndrome (N=243). Results showed patients treated with monlunabant ...

A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to ...

However, shares in Novo Nordisk fell by nearly five per cent last month, after the company reported disappointing results from a phase 2a trial of its experimental obesity pill, monlunabant.

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced the FDA approval of its new biologic treatment, EBGLYSS™ (lebrikizumab-lbkz), for patients 12 years and older... ByInvesting.com • 14 ...